134 related articles for article (PubMed ID: 29603574)
1. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
[TBL] [Abstract][Full Text] [Related]
3. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract][Full Text] [Related]
4. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
Fan H; Xing T; Hong H; Duan C; Zhao W; Zhao Q; Wang X; Huang C; Zhu S; Jin M; Su Y; Gao C; Ma X
Pediatr Hematol Oncol; 2022 May; 39(4):343-356. PubMed ID: 34752187
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
6. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of the determination of bone marrow lesion in patients with neuroblastoma based on the gene PHOX2B and TH expression].
Druĭ AE; Shorikov EV; Tsaur GA; Popov AM; Tuponogov SN; Savel'ëv LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2014; 60(2):57-62. PubMed ID: 24919263
[TBL] [Abstract][Full Text] [Related]
8. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
9. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
10. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
11. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
[TBL] [Abstract][Full Text] [Related]
12. PHOX2B reliably distinguishes neuroblastoma among small round blue cell tumours.
Hung YP; Lee JP; Bellizzi AM; Hornick JL
Histopathology; 2017 Nov; 71(5):786-794. PubMed ID: 28640941
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
Lee NH; Son MH; Choi YB; Yi E; Lee JW; Yoo KH; Sung KW; Koo HH
Cancer Res Treat; 2016 Oct; 48(4):1399-1407. PubMed ID: 27034145
[TBL] [Abstract][Full Text] [Related]
14. PHOX2B Is Associated with Neuroblastoma Cell Differentiation.
Yang L; Ke XX; Xuan F; Tan J; Hou J; Wang M; Cui H; Zhang Y
Cancer Biother Radiopharm; 2016 Mar; 31(2):44-51. PubMed ID: 26910576
[TBL] [Abstract][Full Text] [Related]
15. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
16. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract][Full Text] [Related]
18. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
[TBL] [Abstract][Full Text] [Related]
19. PHOX2B is a reliable immunomarker in distinguishing peripheral neuroblastic tumours from CNS embryonal tumours.
Alexandrescu S; Paulson V; Dubuc A; Ligon A; Lidov HG
Histopathology; 2018 Sep; 73(3):483-491. PubMed ID: 29758594
[TBL] [Abstract][Full Text] [Related]
20. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
